International bonds: Celgene, 4% 15aug2023, USD
US151020AJ30

DATA PLATFORM FOR FINANCIAL MARKET PROFESSIONALS AND INVESTORS

High performance interface for global bond market screening
Full information on close to 500,000 bonds from 180 countries
100% coverage of Eurobonds worldwide
Over 300 primary sources of prices
Ratings data from all international and local ratings agencies
Stock market data from 100 world trading floors
Intuitive, high speed user interface
Data access via the website, mobile application and add-in for Microsoft Excel

Files

Prospectus Supplement

Trading chart

Stock exchange selection

More about Cbonds Estimation

Bond is not traded; the issue is redeemed

Data display in a chart | table

Work with the chart: switching the price, period, issue comparison

Customize fields in the table

Found: {{ graphTablePointsTotal }}

Show all fields

* Data is not available within the selected subscription

Latest data on

Issue information

Profile

Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Borrower

Go to the issuer page
Celgene
Full issuer name

Celgene Corporation
Sector

corporate
Industry

Healthсare

Volume

Placement amount

700,000,000 USD
Outstanding amount

63,914,000 USD

Nominal

Minimum Settlement Amount

2,000 USD
Outstanding face value

*** USD
Par amount, integral multiple

*** USD
Nominal

1,000 USD

Cash flow parameters

Reference rate

***
Coupon Rate

***
Day count fraction

***
Interest Accrual Date

***

Coupon frequency

*** time(s) per year
Payment currency

***
Delay days

*** days
Maturity date

***
Early redemption date

***

Cash flow

Calculations for international bonds are made according to the minimum trading lot

Early redemption terms

***

DATA PLATFORM FOR FINANCIAL MARKET PROFESSIONALS AND INVESTORS

High performance interface for global bond market screening
Full information on close to 500,000 bonds from 180 countries
100% coverage of Eurobonds worldwide
Over 300 primary sources of prices
Ratings data from all international and local ratings agencies
Stock market data from 100 world trading floors
Intuitive, high speed user interface
Data access via the website, mobile application and add-in for Microsoft Excel

Placement

Placement method

Open subscription
Placement type

Public
Placement format

book building
Order book

*** (***) - *** (***)
Coupon (Yield) Guidance

***% - ***% (*** - ***%)
Placement

*** - ***
Initial issue price (yield)

(***%)
Bids

*** USD
Number of bids

***
Geographic breakdown

***
Investor breakdown

***
Listing

***

Participants

Bookrunner

***, ***, ***, ***
Depository

***, ***, ***

Conversion and exchange

Convertion date

***
Initial premium

***%
Convertible until

***
Lock-up

*** days
Conversion terms

***
Exchanged to

Bristol Myers Squibb, 4% 15aug2023, USD

Covenants

Change of Control
***
Collective Action Clause
***
Covenant Suspension/Fall-Away
***
Cross Default
***
Designation of Restricted and Unrestricted Subsidiaries
***
Events of Default
***
Financial Covenants
***
Limitation on Business Activities
***
Limitation on Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries
***
Limitation on Indebtedness
***
Limitation on Investments
***
Limitation on Liens
***
Limitation on Restricted Payments
***
Limitation on Sale of Assets
***
Limitation on Sale/Leaseback
***
Limitation on Subsidiary Debt
***
Limitation on layering (anti-layering)
***
Limitations on transactions with affiliates
***
Merger Restrictions
***
Others
***
Rating Trigger
***

Additional information

***

Latest issues

Show all

News

06/10/2020	S&P Global Ratings revised outlook on Celgene to negative and affirmed at "A+" (Foreign Currency LT) credit rating
06/10/2020	S&P Global Ratings revised outlook on Celgene to negative and affirmed at "A+" (Local Currency LT) credit rating
16/03/2020	Moody's Investors Service withdrew LT- local currency credit rating for Celgene
09/12/2019	Moody's Investors Service upgrades LT- local currency credit rating of Celgene to "A3" from "Baa2"
22/11/2019	S&P Global Ratings upgrades Foreign Currency LT credit rating of Celgene to "A+" from "BBB+"; outlook stable

All organization news

Identifiers

Registration

***
Date of program registration

***
ISIN

***
CUSIP

***
CUSIP 144A

***
CFI

DBFUGR
FIGI

BBG004XMK8W1
WKN

A1HPPF
SEDOL

BCVYHB4
Ticker

CELG 4 08/15/23
Type of security by CBR

***

Show more Hide

Ratings

Do not show withdrawn ratings

Bond classification

Senior Unsecured
Registered
Coupon bonds
Trace-eligible
Amortization
Callable
CDO
Convertible
Dual currency bonds
Floating rate
For qualified investors (CIS region)
Foreign bonds
Green bonds
Indexed
Supranational bond issues
Mortgage bonds
Perpetual
Payment-in-kind
Non-Marketable Securities
Redemption Linked
Restructuring
Retail bonds
Covered
Securitization
Structured product
Subordinated
Sukuk